😱 💉100% effective HIV prevention might just be possible, claims Gilead Sciences, Inc., announcing the results from the clinical trials of the company’s Lenacapavir.
Twice-yearly injectable Lenacapavir and two other drugs, once-daily oral Descovy and Truvada, were randomly distributed among more than 5,300 women aged 16 to 25 in #SouthAfrica and #uganda . Zero cases of HIV infection were reported in the Lenacapavir group, compared with Truvada (16 cases) and Descovy (39 cases).
🙏🏼😍 Further results are expected to be released in late 2024 or early 2025:
https://www.gilead.com/news-and-press/press-room/press-releases/2024/6/gileads-twiceyearly-lenacapavir-demonstrated-100-efficacy-and-superiority-to-daily-truvada-for-hiv-prevention
